Revalesio is a clinical-stage pharmaceutical company committed to creating treatments for neurological diseases and conditions that lack adequate therapeutic options.

Our therapies address cellular imbalances related to mitochondrial dysfunction and thereby modulate the immune response. They have been shown to protect neurons in models of chronic neurological diseases and improve recovery in acute neurological injury. We are partnering with internationally renowned scientists in biomedical research in a concerted effort to improve the lives of millions.


Team Member
Greg Archambeau
Team Member
Bert van den Bergh
Executive Chairman of the Board
Team Member
Andreas Kalmes, PhD
Vice President of Drug Development
Team Member
Supurna Ghosh, PhD
Vice President of Translational Medicine
Team Member
Brian Polzak
Executive Business Advisor
Team Member
Neil Price
Vice President of Finance

of directors

Bert van den Bergh
Executive Chairman of the Board
Tom Bumol, PhD
Board Director, Science and Technology Committee Chairperson
William R. Gallacher
Board Director
Matt Ireland
Board Director, Finance Committee Chairperson
James A. Nordstrom
Board Director
Eric Russell
Board Director, Revalesio Founder
Jane Taylor
Board Director, Governance Committee Chairperson

advisory board

Tom Bumol, PhD (Chairperson)
Executive VP and Director of Allen Institute for Immunology, Former SVP of Eli Lilly
Jack Antel, MD
Montreal Neurological Institute & Hospital, McGill University: Professor; ACTRIMS: President
Merit Cudkowicz, MD, MSc
Mass General Hospital: Chief of Neurology & Director of Sean M. Healey ALS Center
Henry McFarland, MD
National Institute of Neurological Disorders & Stroke: Retired Director
Kalipada Pahan, PhD
Rush University Medical College: Neurological Sciences; Professor & Floyd Davis Endowed Chair
Raymond Roos, MD
University of Chicago: Professor; ALS/Motor Neuron Disease Clinic: Director
Eric Shoubridge, PhD
Montreal Neurological Institute & Hospital, McGill University: Professor

Contact us

Want to know more about our company, technology, products or potential partnership opportunities?

You can
reach us at